A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation-Reference-Cited by-同舟云学术

A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation

Published:2016-04-28 Issue:1 Volume:58 Page:153-161
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Weisel Katja,Doyen Chantal,Dimopoulos Meletios,Yee Adrian,Lahuerta Juan José,Martin Amber,Travers Karin,Druyts Eric,Toor Kabirraaj,Abildgaard Niels,Lu Jin,Van Droogenbroeck Jan,Geraldes Catarina,Petrini Mario,Voillat Laurent,Voog Eric,Facon Thierry

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://tandfonline.com/doi/pdf/10.1080/10428194.2016.1177772

Reference43 articles.

1. Maintenance Therapy for Multiple Myeloma

2. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

3. “Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment?”

4. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenalidomide or Thalidomide for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma? An Overview of Systematic Reviews;Value in Health Regional Issues;2024-09

2. Comparative efficacy of VMP vs. Rd in newly diagnosed, autologous stem cell transplant-ineligible multiple myeloma patients: a prematurely terminated randomized controlled study, CAREMM-2002 study;Blood Research;2024-07-17

3. Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report;Oncohematology;2023-12-08

4. Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review;Life;2023-11-27

5. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study;Journal of Cancer Research and Clinical Oncology;2023-07-07